Amsurg Stock Keeps “Neutral” Rating

Zacks has reaffirmed its “neutral” rating of Amsurg, according to a Zolmax News report.

Advertisement

Amsurg reported a revenue increase in its second quarter report earlier this year, which was ahead of the Zacks Consensus Estimate. Despite this growth, analysts were concerned with reduction in workers’ compensation reimbursement and the impact of sequestration, according to the report.

An alliance with a hospital system was praised, but reimbursement issues overshadowed this growth potential.

More Articles on Surgery Centers:
Crisis Averted? How Raising the Debt Limit & Ending Government Shutdown Impacts ASCs

How Gastroenterologists Can Prepare for Healthcare Reform: Q&A With Dr. Patrick Takahashi

Outlook on the ASC Industry for 2014: Biggest Concerns & Best Strategies

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.